Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Anti-tumor Activity of JIN-A02 in EGFR Mutant Advanced NSCLC
NCT05394831Phase 2Recruiting
- Sponsor
- J INTS BIO
- Start
- Jul 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of JIN-A02 in non-small cell lung cancer (NSCLC), sponsored by J INTS BIO. Primary endpoints: Maximum Tolerable Dose at 28 days, Adverse Events Rate at 28 days and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
JIN-A02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05394831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394831.